Cargando…
The association of circulating levels of complement-C1q TNF-related protein 5 (CTRP5) with nonalcoholic fatty liver disease and type 2 diabetes: a case–control study
BACKGROUND: It is well-established that nonalcoholic fatty liver disease (NAFLD) is associated with type 2 diabetes mellitus (T2DM). Complement-C1q TNF-related protein 5 (CTRP5) is a novel adipokine involved in the regulation of lipid and glucose metabolism. We aimed to assess plasma levels of CTRP5...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4660841/ https://www.ncbi.nlm.nih.gov/pubmed/26613006 http://dx.doi.org/10.1186/s13098-015-0099-z |
_version_ | 1782402885879857152 |
---|---|
author | Emamgholipour, Solaleh Moradi, Nariman Beigy, Maani Shabani, Parisa Fadaei, Reza Poustchi, Hossein Doosti, Mahmood |
author_facet | Emamgholipour, Solaleh Moradi, Nariman Beigy, Maani Shabani, Parisa Fadaei, Reza Poustchi, Hossein Doosti, Mahmood |
author_sort | Emamgholipour, Solaleh |
collection | PubMed |
description | BACKGROUND: It is well-established that nonalcoholic fatty liver disease (NAFLD) is associated with type 2 diabetes mellitus (T2DM). Complement-C1q TNF-related protein 5 (CTRP5) is a novel adipokine involved in the regulation of lipid and glucose metabolism. We aimed to assess plasma levels of CTRP5 in patients with NAFLD (n = 22), T2DM (n = 22) and NAFLD with T2DM (NAFLD + T2DM) (n = 22) in comparison with healthy subjects (n = 21) and also to study the association between CTRP5 levels and NAFLD and diabetes-related parameters. METHODS: All subjects underwent anthropometric assessment, biochemical evaluation and liver stiffness (LS) measurement. Insulin resistance (IR) was determined by the homeostasis model assessment (HOMA). Plasma CTRP5 levels were measured by enzyme-linked immunosorbent assay. RESULTS: We found significantly lower plasma levels of CTRP5 in patients with NAFLD + T2DM, NAFLD and T2DM (122.52 ± 1.92, 124.7 ± 1.82 and 118.31 ± 1.99 ng/ml, respectively) in comparison with controls (164.96 ± 2.95 ng/ml). In the whole study population, there was a significant negative correlations between CTRP5 and body mass index (r = −0.337; p = 0.002), fasting blood glucose (FBG) (r = −0.488; p < 0.001), triglyceride (TG) (r = −0.245; p = 0.031), HOMA-IR (r = −0.492; p < 0.001), insulin(r = −0.338; p = 0.002), LS (r = −0.544; p < 0.001), alanine aminotransferase (ALT) (r = −0.251; p = 0.027), waist-to-hip ratio (WHR) (r = −0.352; p = 0.002) and waist circumference (WC) (r = −0.357; p = 0.001). After adjustment for BMI, decrease in circulating levels of CTRP5 remained as a significant risk factor for NAFLD, T2DM and NAFLD + T2DM. The receiver operating characteristic (ROC) curves of circulating CTRP5 in predicting NAFLD and T2DM demonstrated an area under the curve (AUC) of 0.763 in T2DM, and 0.659 in NAFLD + T2DM. CONCLUSIONS: It appears that the decreased levels of CTRP5 contribute to the increased risk of T2DM and NAFLD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13098-015-0099-z) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4660841 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-46608412015-11-27 The association of circulating levels of complement-C1q TNF-related protein 5 (CTRP5) with nonalcoholic fatty liver disease and type 2 diabetes: a case–control study Emamgholipour, Solaleh Moradi, Nariman Beigy, Maani Shabani, Parisa Fadaei, Reza Poustchi, Hossein Doosti, Mahmood Diabetol Metab Syndr Research BACKGROUND: It is well-established that nonalcoholic fatty liver disease (NAFLD) is associated with type 2 diabetes mellitus (T2DM). Complement-C1q TNF-related protein 5 (CTRP5) is a novel adipokine involved in the regulation of lipid and glucose metabolism. We aimed to assess plasma levels of CTRP5 in patients with NAFLD (n = 22), T2DM (n = 22) and NAFLD with T2DM (NAFLD + T2DM) (n = 22) in comparison with healthy subjects (n = 21) and also to study the association between CTRP5 levels and NAFLD and diabetes-related parameters. METHODS: All subjects underwent anthropometric assessment, biochemical evaluation and liver stiffness (LS) measurement. Insulin resistance (IR) was determined by the homeostasis model assessment (HOMA). Plasma CTRP5 levels were measured by enzyme-linked immunosorbent assay. RESULTS: We found significantly lower plasma levels of CTRP5 in patients with NAFLD + T2DM, NAFLD and T2DM (122.52 ± 1.92, 124.7 ± 1.82 and 118.31 ± 1.99 ng/ml, respectively) in comparison with controls (164.96 ± 2.95 ng/ml). In the whole study population, there was a significant negative correlations between CTRP5 and body mass index (r = −0.337; p = 0.002), fasting blood glucose (FBG) (r = −0.488; p < 0.001), triglyceride (TG) (r = −0.245; p = 0.031), HOMA-IR (r = −0.492; p < 0.001), insulin(r = −0.338; p = 0.002), LS (r = −0.544; p < 0.001), alanine aminotransferase (ALT) (r = −0.251; p = 0.027), waist-to-hip ratio (WHR) (r = −0.352; p = 0.002) and waist circumference (WC) (r = −0.357; p = 0.001). After adjustment for BMI, decrease in circulating levels of CTRP5 remained as a significant risk factor for NAFLD, T2DM and NAFLD + T2DM. The receiver operating characteristic (ROC) curves of circulating CTRP5 in predicting NAFLD and T2DM demonstrated an area under the curve (AUC) of 0.763 in T2DM, and 0.659 in NAFLD + T2DM. CONCLUSIONS: It appears that the decreased levels of CTRP5 contribute to the increased risk of T2DM and NAFLD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13098-015-0099-z) contains supplementary material, which is available to authorized users. BioMed Central 2015-11-25 /pmc/articles/PMC4660841/ /pubmed/26613006 http://dx.doi.org/10.1186/s13098-015-0099-z Text en © Emamgholipour et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Emamgholipour, Solaleh Moradi, Nariman Beigy, Maani Shabani, Parisa Fadaei, Reza Poustchi, Hossein Doosti, Mahmood The association of circulating levels of complement-C1q TNF-related protein 5 (CTRP5) with nonalcoholic fatty liver disease and type 2 diabetes: a case–control study |
title | The association of circulating levels of complement-C1q TNF-related protein 5 (CTRP5) with nonalcoholic fatty liver disease and type 2 diabetes: a case–control study |
title_full | The association of circulating levels of complement-C1q TNF-related protein 5 (CTRP5) with nonalcoholic fatty liver disease and type 2 diabetes: a case–control study |
title_fullStr | The association of circulating levels of complement-C1q TNF-related protein 5 (CTRP5) with nonalcoholic fatty liver disease and type 2 diabetes: a case–control study |
title_full_unstemmed | The association of circulating levels of complement-C1q TNF-related protein 5 (CTRP5) with nonalcoholic fatty liver disease and type 2 diabetes: a case–control study |
title_short | The association of circulating levels of complement-C1q TNF-related protein 5 (CTRP5) with nonalcoholic fatty liver disease and type 2 diabetes: a case–control study |
title_sort | association of circulating levels of complement-c1q tnf-related protein 5 (ctrp5) with nonalcoholic fatty liver disease and type 2 diabetes: a case–control study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4660841/ https://www.ncbi.nlm.nih.gov/pubmed/26613006 http://dx.doi.org/10.1186/s13098-015-0099-z |
work_keys_str_mv | AT emamgholipoursolaleh theassociationofcirculatinglevelsofcomplementc1qtnfrelatedprotein5ctrp5withnonalcoholicfattyliverdiseaseandtype2diabetesacasecontrolstudy AT moradinariman theassociationofcirculatinglevelsofcomplementc1qtnfrelatedprotein5ctrp5withnonalcoholicfattyliverdiseaseandtype2diabetesacasecontrolstudy AT beigymaani theassociationofcirculatinglevelsofcomplementc1qtnfrelatedprotein5ctrp5withnonalcoholicfattyliverdiseaseandtype2diabetesacasecontrolstudy AT shabaniparisa theassociationofcirculatinglevelsofcomplementc1qtnfrelatedprotein5ctrp5withnonalcoholicfattyliverdiseaseandtype2diabetesacasecontrolstudy AT fadaeireza theassociationofcirculatinglevelsofcomplementc1qtnfrelatedprotein5ctrp5withnonalcoholicfattyliverdiseaseandtype2diabetesacasecontrolstudy AT poustchihossein theassociationofcirculatinglevelsofcomplementc1qtnfrelatedprotein5ctrp5withnonalcoholicfattyliverdiseaseandtype2diabetesacasecontrolstudy AT doostimahmood theassociationofcirculatinglevelsofcomplementc1qtnfrelatedprotein5ctrp5withnonalcoholicfattyliverdiseaseandtype2diabetesacasecontrolstudy AT emamgholipoursolaleh associationofcirculatinglevelsofcomplementc1qtnfrelatedprotein5ctrp5withnonalcoholicfattyliverdiseaseandtype2diabetesacasecontrolstudy AT moradinariman associationofcirculatinglevelsofcomplementc1qtnfrelatedprotein5ctrp5withnonalcoholicfattyliverdiseaseandtype2diabetesacasecontrolstudy AT beigymaani associationofcirculatinglevelsofcomplementc1qtnfrelatedprotein5ctrp5withnonalcoholicfattyliverdiseaseandtype2diabetesacasecontrolstudy AT shabaniparisa associationofcirculatinglevelsofcomplementc1qtnfrelatedprotein5ctrp5withnonalcoholicfattyliverdiseaseandtype2diabetesacasecontrolstudy AT fadaeireza associationofcirculatinglevelsofcomplementc1qtnfrelatedprotein5ctrp5withnonalcoholicfattyliverdiseaseandtype2diabetesacasecontrolstudy AT poustchihossein associationofcirculatinglevelsofcomplementc1qtnfrelatedprotein5ctrp5withnonalcoholicfattyliverdiseaseandtype2diabetesacasecontrolstudy AT doostimahmood associationofcirculatinglevelsofcomplementc1qtnfrelatedprotein5ctrp5withnonalcoholicfattyliverdiseaseandtype2diabetesacasecontrolstudy |